Em 1\u00ba de julho de 2025, a Administra\u00e7\u00e3o Nacional de Seguro M\u00e9dico e a Comiss\u00e3o Nacional de Sa\u00fade lan\u00e7aram as \"V\u00e1rias Medidas para Apoiar o Desenvolvimento de Alta Qualidade de Medicamentos Inovadores\", marcando uma nova fase no ecossistema chin\u00eas de inova\u00e7\u00e3o farmac\u00eautica. Este documento de pol\u00edtica adota uma abordagem sistem\u00e1tica para abordar os tr\u00eas principais pontos problem\u00e1ticos no desenvolvimento de medicamentos inovadores \u2014 desafios em P&D, ado\u00e7\u00e3o hospitalar e reembolso \u2014 aproveitando o seguro m\u00e9dico para impulsionar a moderniza\u00e7\u00e3o industrial e fornecer robusto apoio \u00e0 constru\u00e7\u00e3o de uma China Saud\u00e1vel.<\/p>\n
Ao projetar as regras de renova\u00e7\u00e3o, as autoridades de seguro m\u00e9dico demonstraram sabedoria institucional: as renova\u00e7\u00f5es simplificadas apresentaram uma redu\u00e7\u00e3o m\u00e9dia de pre\u00e7o de apenas 1,2%, com quase 80% de medicamentos renovados pelos pre\u00e7os originais. Medicamentos inovadores da categoria 1 podem ser renegociados para responder \u00e0s mudan\u00e7as do mercado. Esse \"ajuste flex\u00edvel\" protege a seguran\u00e7a do fundo, evitando ao mesmo tempo cortes excessivos de pre\u00e7o que poderiam sufocar o impulso \u00e0 inova\u00e7\u00e3o. Como afirmou Huang Xinyu, Diretor da Ag\u00eancia Nacional de Seguro M\u00e9dico: \"Precisamos garantir que os medicamentos inovadores verdadeiramente valiosos do ponto de vista cl\u00ednico recebam retornos razo\u00e1veis\".<\/p>\n
Sistema de Pagamento Multin\u00edvel Rompe Impasse no Pagamento<\/p>\n
Avan\u00e7os Inovadores no Contexto Global<\/p>\n
The synergistic innovation between medical insurance and commercial insurance is even more groundbreaking: data sharing enables \u201cone-stop settlement,\u201d allowing patients to seamlessly coordinate medical insurance and commercial insurance payments at healthcare facilities; intelligent supervision platforms ensure fund security, preventing commercial insurance from becoming a target for fraud. This model, where \u201cdata runs the errands while patients reduce their burden,\u201d is fundamentally reshaping the underlying logic of healthcare security.<\/p>\n
On the R front, the opening of medical insurance data marks a milestone. Through disease spectrum analysis and aggregation of medication needs, pharmaceutical companies can strategically align their R pipelines, avoiding homogenized competition. In 2024, China approved 48 Class 1 innovative drugs\u2014a fivefold increase from 2018\u2014a surge directly empowered by policy. The synergy between national science and technology initiatives and healthcare policies has forged a complete chain from \u201cbasic research to clinical translation to market application.\u201d<\/p>\n
Reforms in clinical application are equally noteworthy: breaking the \u201cone drug, two specifications\u201d restriction, enforcing a three-month adjustment requirement for pharmaceutical committees, and establishing a case-by-case negotiation mechanism\u2014these measures directly address the persistent issue of drugs being covered by insurance but not adopted in hospitals. When DRG\/DIP payment reforms are combined with special case negotiations, healthcare institutions\u2019 enthusiasm for using innovative drugs is fully mobilized. In 2024, fund expenditures for negotiated drugs during the agreement period exceeded 100 billion yuan, validating the effectiveness of these policies.<\/p>\n
China\u2019s innovative drugs are transitioning from \u201cfollowing\u201d to \u201cleading.\u201d Over 90 overseas licensing deals totaling more than $50 billion in 2024 signify that Chinese pharmaceutical companies have attained global competitiveness. Medical insurance authorities safeguard the overseas expansion of innovative drugs through price confidentiality mechanisms and the development of cross-border transaction platforms.<\/p>\n
In this global competition, the unique advantages of Hong Kong and Macao, China, are becoming increasingly prominent. Leveraging the international capital and intellectual property protection systems of Hong Kong and Macao, China\u2019s innovative drugs are accelerating their integration into the global industrial chain. This \u201cdual circulation\u201d strategy not only consolidates the domestic market foundation but also enhances China\u2019s voice in shaping international rules.<\/p>\n
Despite remarkable achievements, China\u2019s innovative drug development still faces challenges such as homogenized competition and insufficient payment capacity. Data indicates that in 2024, per capita funding for resident medical insurance reached only 1,070 yuan, while utilization rates for commercial health insurance funds remained below 50%. The multi-source payment system urgently requires refinement. In response, policies explicitly advocate \u201csupporting genuine innovation and differentiated innovation,\u201d guiding resources toward high-value innovations through health technology assessments and real-world data applications.<\/p>\n
Looking ahead, medical insurance reform will continue to function as a \u201cstrategic purchaser\u201d: dynamic adjustment mechanisms will become more precise, commercial insurance directories will serve as key outlets for innovative drugs, and data empowerment will reshape R paradigms. When medical insurance, healthcare, and pharmaceuticals synergize, China\u2019s pharmaceutical industry will achieve a historic leap from a \u201cmajor producer of generic drugs\u201d to an \u201cinnovation powerhouse.\u201d<\/p>\n
The ultimate goal of this reform is to ensure every patient timely access to quality medicines. As Wang Guodong, Deputy Director of the National Healthcare Security Administration\u2019s Medical Insurance Center, stated, \u201cEvery penny of the medical insurance fund must be spent where it matters most.\u201d As innovative drugs become powerful tools for safeguarding lives and multi-tiered protections weave a safety net for health, the vision of a Healthy China is rapidly becoming a reality.<\/p>","protected":false},"excerpt":{"rendered":"
No More Waiting for Effective Medicines: Healthcare Reform Accelerates China’s Pace of Innovative Drug Development On July 1, 2025, the National Healthcare Security Administration and the National Health Commission released the \u201cSeveral Measures to Support the High-Quality Development of Innovative Drugs,\u201d marking a new phase in China’s pharmaceutical innovation ecosystem. This policy document employs a […]<\/p>","protected":false},"author":4,"featured_media":640,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[62],"tags":[],"class_list":["post-639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry-dynamics"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/posts\/639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/comments?post=639"}],"version-history":[{"count":0,"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/posts\/639\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/media\/640"}],"wp:attachment":[{"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/media?parent=639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/categories?post=639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medicalsoho.com\/pt\/wp-json\/wp\/v2\/tags?post=639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}